PubMed Health⌕ Search

Biomedical subjects

E Lens

Publications and source records attributed to E Lens.

5 recordsLinked to original sources
PubMed1991

[Epidemiological surveillance of antibiotic resistance in a general hospital for the assessment of 'blind' antibiotics policy].

A study was made of the epidemiology of gentamicin-resistant Gram-negative rods in a large general hospital over the last 12 years, and of the consequences of the presence of these bacteria for antibiotics policies, especially the use of gentamicin. Resistant bacteria were endemic at a low level: of the clinical isolates, 670 from 488 patients contained resistant bacteria, 2% of all Gram-negative rod isolates. Sporadically there were minor epidemics. Especially seriously ill, elderly patients became infected. Every year multiresistant bacteria contributed to a number of deaths. The choice of gentamicin as a drug of first, blind, choice in life-threatening infections remained justified. Continuous monitoring of Gram-negative rods is an important instrument for a preventive policy.

Drug Resistance, Microbial↗
PubMed1990

Prospective trial of recombinant leucocyte interferon in chronic hepatitis B: a long-term follow-up study.

Twenty-one adult patients with chronic hepatitis B and active viral replication as indicated by positivity for hepatitis B e antigen and hepatitis B virus DNA, with increased DNA polymerase levels for more than 6 months, were entered into a prospective trial of low-dose recombinant human alpha-interferon therapy. All patients were treated with 5 million units of recombinant interferon alfa-2b given subcutaneously every other day for 12 weeks. During treatment, 18 patients (86%) showed a significant reduction of DNA polymerase levels (p less than or equal to 0.001), which reached normal values in ten (48%). After 10 months' mean follow up, seven patients (33%) were hepatitis B e antigen negative and five (24%) subsequently became positive for antibodies to e antigen. By 27 months, nine patients (43%) were both hepatitis B e antigen negative and e antibody positive. Only one patient became permanently negative for hepatitis B surface antigen. One patient relapsed during the second year of follow up. Side effects necessitated withdrawal of therapy in two patients: one due to worsening thrombocytopenia after two doses of interferon (data omitted from the study results) and one due to a local reaction at the injection sites. Our data indicate that small doses of recombinant interferon alfa-2b given during a 12-week period induce a significant reduction in viral replication and approximately triple the spontaneous seroconversion rate observed in patients with chronic hepatitis B.

Alanine Transaminase↗
PubMed1989

Prospective trial of recombinant leucocyte interferon in chronic hepatitis B: a 10-month follow-up study.

Twenty-one adult patients with chronic hepatitis B and active viral replication as indicated by the presence of hepatitis Be antigen (HBeAg), increased DNA polymerase (DNAp) and positive hepatitis B virus DNA (HBV-DNA) for more than 6 months, were entered into a prospective trial of recombinant human interferon therapy. Ten patients had chronic persistent or chronic lobular hepatitis, 8 chronic active hepatitis and 3 postnecrotic cirrhosis. All cases were treated with 5 x 10(6) units of recombinant interferon alfa-2B given subcutaneously every other day for 12 weeks. During treatment, 18 patients (86%) showed a significant reduction of DNAp levels, which reached normal values in 10 patients (48%). Viral replication was controlled over a 10-month follow-up period in 7 out of 21 patients (33%). Of these 7, five patients became HBeAg negative and HBeAb positive. HBsAg disappeared in one patient. The only serious adverse effect was thrombocytopenia in one patient in whom rapid recovery occurred when interferon was withdrawn. Treatment was also terminated in a second patient because of local reactions at the injection sites occurring after 10 weeks of therapy. Our data indicate that relatively small doses of recombinant alfa-2B interferon given during a 12-week period induce a significant reduction in viral replication and might approximately triple the spontaneous seroconversion rate observed in patients with chronic hepatitis B.

Adult↗